SNCA and Parkinson disease: (i)Developing neuroprotective and disease-modifying therapies intendedfor slowing or ceasing the progression of PD; (ii) Investigating novelpharmacological agents, gene therapies, and biologics targeting specificpathways implicated in PD pathology, such as α-synuclein aggregation,mitochondrial dysfunction, and neuroinflammation; (iii) Repurposingexisting drugs or compounds with potential neuroprotective effectsfor PD treatment.